Cover Image
市場調查報告書

OncoSec Medical Inc. 的產品平台分析

OncoSec Medical Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320920
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
OncoSec Medical Inc. 的產品平台分析 OncoSec Medical Inc. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 29 Pages
簡介

OncoSec Medical Inc.是總公司設立於美國的生物科技企業,所說的黑色素瘤和梅克爾細胞癌,皮膚T細胞淋巴癌等皮膚癌的晚期治療藥。

本報告提供OncoSec Medical Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

OncoSec Medical Inc.的基本資料

  • OncoSec Medical Inc.概要
  • 主要資訊
  • 企業資料

OncoSec Medical Inc.:R&D概要

  • 主要的治療範圍

OncoSec Medical Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

OncoSec Medical Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

OncoSec Medical Inc.:藥物簡介

  • DNA IL-12
  • DNA IL-12 + pembrolizumab
  • DNA IL-12 + Anti-CTLA-4 Antibody
  • DNA IL-12 + Anti-PD-1 Antibody

OncoSec Medical Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

OncoSec Medical Inc.:最新的開發平台資訊

OncoSec Medical Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

目錄
Product Code: GMDHC06629CDB

Summary

Global Markets Direct's, 'OncoSec Medical Inc. - Product Pipeline Review - 2014', provides an overview of the OncoSec Medical Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OncoSec Medical Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of OncoSec Medical Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of OncoSec Medical Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the OncoSec Medical Inc.'s pipeline products

Reasons to buy

  • Evaluate OncoSec Medical Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of OncoSec Medical Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the OncoSec Medical Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of OncoSec Medical Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoSec Medical Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of OncoSec Medical Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • OncoSec Medical Inc. Snapshot
    • OncoSec Medical Inc. Overview
    • Key Information
    • Key Facts
  • OncoSec Medical Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • OncoSec Medical Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • OncoSec Medical Inc. - Pipeline Products Glance
    • OncoSec Medical Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • OncoSec Medical Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • OncoSec Medical Inc. - Drug Profiles
    • DNA IL-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNA IL-12 + pembrolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNA IL-12 + Anti-CTLA-4 Antibody
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNA IL-12 + Anti-PD-1 Antibody
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • OncoSec Medical Inc. - Pipeline Analysis
    • OncoSec Medical Inc. - Pipeline Products by Target
    • OncoSec Medical Inc. - Pipeline Products by Route of Administration
    • OncoSec Medical Inc. - Pipeline Products by Molecule Type
    • OncoSec Medical Inc. - Pipeline Products by Mechanism of Action
  • OncoSec Medical Inc. - Recent Pipeline Updates
  • OncoSec Medical Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • OncoSec Medical Inc., Key Information
  • OncoSec Medical Inc., Key Facts
  • OncoSec Medical Inc. - Pipeline by Indication, 2014
  • OncoSec Medical Inc. - Pipeline by Stage of Development, 2014
  • OncoSec Medical Inc. - Monotherapy Products in Pipeline, 2014
  • OncoSec Medical Inc. - Combination Treatment Modalities in Pipeline, 2014
  • OncoSec Medical Inc. - Phase II, 2014
  • OncoSec Medical Inc. - Phase I, 2014
  • OncoSec Medical Inc. - Preclinical, 2014
  • OncoSec Medical Inc. - Pipeline by Target, 2014
  • OncoSec Medical Inc. - Pipeline by Route of Administration, 2014
  • OncoSec Medical Inc. - Pipeline by Molecule Type, 2014
  • OncoSec Medical Inc. - Pipeline Products by Mechanism of Action, 2014
  • OncoSec Medical Inc. - Recent Pipeline Updates, 2014
  • OncoSec Medical Inc., Other Locations

List of Figures

  • OncoSec Medical Inc. - Pipeline by Top 10 Indication, 2014
  • OncoSec Medical Inc. - Pipeline by Stage of Development, 2014
  • OncoSec Medical Inc. - Combination Treatment Modalities in Pipeline, 2014
  • OncoSec Medical Inc. - Pipeline by Top 10 Target, 2014
  • OncoSec Medical Inc. - Pipeline by Top 10 Route of Administration, 2014
  • OncoSec Medical Inc. - Pipeline by Top 10 Molecule Type, 2014
  • OncoSec Medical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top